Vaccine Safety Body Proposed To Remove FDA "Conflict Of Interest"
This article was originally published in The Pink Sheet Daily
A proposal to move post-market vaccine safety surveillance to an independent board will be discussed by the National Vaccine Advisory Committee at its next meeting. FDA and CDC are defending the current system as enabling communication between risk management and risk assessment staff.
You may also be interested in...
Report updates 2001 reports that were “unclear” about link between thimerosal and neurodevelopment disorders.
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”